ERBB2 and cholangiocarcinoma: In conclusion, lapatinib results in definite reduction of p-HER2, p-ERK and p-Akt in HER2-overexpressed cholangiocarcinoma, and thus induces the G1 cell cycle arrest and apoptosis in a concentration and time-dependent manner (Figure 3M).